Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
Keya Medical announced that it has completed a $30 Million Series C Funding Round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
On Oct. 17 and 18, the Chengdu Science and Technology Bureau hosted the 2020 DEMO China Innovation Finals, bringing together leading companies across the country.
On Sept. 18, Keya Medical was recognized as the winner of of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.
CuraRad-ICH is now available on the Nuance AI Marketplace for Diagnostic Imaging, the first and largest workflow-integrated market.
Keya Medical announced on Aug. 13 that it has raised over $20 million in Series B+ funding.